» Articles » PMID: 38312182

Treatment and Outcome of Light Chain Deposition Disease in the Era of Novel Agents and Transplant

Overview
Specialty Hematology
Date 2024 Feb 5
PMID 38312182
Authors
Affiliations
Soon will be listed here.
References
1.
Lorenz E, Gertz M, Fervenza F, Dispenzieri A, Lacy M, Hayman S . Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant. 2008; 23(6):2052-7. DOI: 10.1093/ndt/gfm918. View

2.
Masood A, Ehsan H, Iqbal Q, Salman A, Hashmi H . Treatment of Light Chain Deposition Disease: A Systematic Review. J Hematol. 2022; 11(4):123-130. PMC: 9451548. DOI: 10.14740/jh1038. View

3.
Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos M . Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica. 2008; 94(2):300-2. PMC: 2635400. DOI: 10.3324/haematol.13548. View

4.
Matthai S, Jacob S, Devasia A, Bindra M, David V, Varughese S . Unmasking and successful management of light chain deposition disease of kidney in pregnancy: a complex case, mirroring the complex needs of pregnancy with kidney disease in India. J Nephrol. 2018; 31(5):785-791. DOI: 10.1007/s40620-018-0532-0. View

5.
Nasr S, Valeri A, Cornell L, Fidler M, Sethi S, DAgati V . Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2011; 7(2):231-9. DOI: 10.2215/CJN.08640811. View